Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265598 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL17887907 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL29709585 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL11059297 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL12904430 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL19127751 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL7148974 | 1.00 | TSHR (0.50) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL28773455 | 0.97 | PDE4A (0.48) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL4049818 | 0.92 | PDE4A (0.44) | TSHRPDE4ATP53CYP2C9ALDH1A1 | |
| SCHEMBL15841482 | 0.91 | TSHR (0.53) | TSHRPDE4ATP53CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118109820-A | Copper etching solution composition for reducing copper corrosion and etching crystallization after stripping and washing | 西陇科学股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-114945560-A | GPR119 agonists | 卡尔优普公司 | 2022-08-26 | — | — | CN | claimed |
| CN-113717381-B | Rhamnosyl linear and dendritic-star polymer, preparation method and application | 中国海洋大学 | 2022-06-21 | — | — | CN | claimed |
| CN-113717381-A | Rhamnosyl linear and dendritic-star polymer, preparation method and application | 中国海洋大学 | 2021-11-30 | — | — | CN | claimed |
| CN-108699028-A | It is substituted 4- phenylpyridine compounds as non-systemic TGR5 agonists | 阿德利克斯公司 | 2018-10-23 | — | — | CN | claimed |
| US-20250223392-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC (CH) | 2025-07-10 | — | — | US | disclosed |
| US-12286501-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2025-04-29 | — | — | US | disclosed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250059330-A1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4481478-A2 | SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2024-12-25 | — | — | EP | disclosed |
| US-12162987-B2 | Silicone hydrogel contact lenses | ALCON INC. (CH) | 2024-12-10 | — | — | US | disclosed |
| EP-4235274-B1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2024-10-09 | — | — | EP | disclosed |
| WO-2016131672-A1 | 2,3,4,5-TETRAHYDROXY-HEXANEDIOIC ACID ESTERS FROM DI-LACTONES OF 2,3,4,5-TETRAHYDROXY-HEXANEDIOIC ACID | BASF SE (DE) | 2016-08-25 | — | — | WO | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-10-29 | — | — | US | disclosed |
| US-8716344-B2 | Class- and isoform-specific HDAC inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120046533-A1 | COMBINED SENSOR AND INFUSION SETS | MEDTRONIC MINIMED, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110160036-A1 | VALVE METAL OXIDE FORMULATION | H.C. STARCK GMBH (DE) | 2011-06-30 | — | — | US | disclosed |
| EP-2318325-A2 | VALVE METAL OXIDE FORMULATION | H.C. Starck GmbH (DE) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010026016-A2 | VALVE METAL OXIDE FORMULATION | H.C. STARCK GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | TSHR 4331/4885PDE4A 4587/4885TP53 1908/4885 |
| US-20150307444-A1 | CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF | HDAC1, HDAC5, HDAC6 | TSHR 3987/4885PDE4A 2225/4885TP53 1611/4885 |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | TSHR 4331/4885PDE4A 4587/4885TP53 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.